Metastatic non-small cell lung cancer (mNSCLC) remains a leading cause of cancer mortality despite advances with targeted therapy and immune checkpoint inhibitors (ICIs). While PD-1/PD-L1 blockade has improved outcomes, most patients ultimately progress, and durable responses remain limited. These challenges highlight ongoing unmet needs in overcoming resistance, tailoring therapy for oncogene-driven tumors, and balancing efficacy with manageable toxicity. Among the most promising emerging agents are bispecific antibodies (BsAbs) and co-stimulatory immune modulators, both of which are designed to enhance anti-tumor immunity through distinct but complementary mechanisms. These next-generation agents aim to restore immune surveillance, reshape the tumor microenvironment, and overcome established resistance mechanisms. In this CE Concepts Journal Club, expert faculty will assess emerging data on bispecific antibodies and co-stimulatory immune modulators presented at the ESMO-IO Congress and interpret safety and efficacy profiles of novel immuno-oncology agents to inform therapeutic decision-making in mNSCLC. This enduring, interactive activity will provide timely insights to support informed care planning and improved outcomes for patients with advanced lung cancer.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Pricing
100% of listed courses are free
18 of 18 courses listed here are free.
Collected from the provider’s public pages
Specialties served/covered
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Recorded-from-live session
- Credit · Up to 1 credit
- MOC · Up to 1 point
-
ReleasedFeb 10, 2026
-
Last day to claim creditFeb 12, 2027 4 months left
-
Creative Educational Concepts, Inc. Evolving Paradigms in Immuno-Oncology: Optimizing Patient Care Through Innovative Delivery Approaches of Immune Checkpoint Inhibitors
-
Creative Educational Concepts, Inc. AI-Powered Precision Learning: Advances in RRMM: Clinical Practice Considerations for Optimizing BCMA Bispecific Antibody Combination Therapy
-
Creative Educational Concepts, Inc. AI-Powered Precision Learning: Cracking the MIBC Code with Smart Navigation of (Neo)adjuvant and Perioperative Immunotherapy Options
